Coronary drug project

Jump to: navigation, search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Coronary drug project On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coronary drug project

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coronary drug project

CDC on Coronary drug project

Coronary drug project in the news

Blogs on Coronary drug project

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Coronary drug project

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Coronary Drug Project

Objective

To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Timeline
Start Date April 1965
End Date March 1985
Status Completed

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000482.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 3
Study Design
Allocation Randomized
Masking Double-Blind
Study Details
Primary Purpose Prevention
Condition Cardiovascular diseases; coronary disease; heart diseases; myocardial infarction; myocardial ischemia
Intervention Drug: estrogen

Drug: clofibrate clofibrate
Drug: dextrothyroxine sodium
Drug: niacin

Population Size 8,341 subjects

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000482.

Eligibility Criteria

Inclusion Criteria

Men, ages 30-64, three months beyond most recent myocardial infarction

References


Linked-in.jpg